Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: OTC Stock Picks Newsletter Announces Awesome Penny Stock Pick Mannkind Corporati

This is nothing new,we've all heard that you can take Afrezza,eat nothing,and still no hypoglycemia.But it's interesting to see how much it lowered HBA1C.

Abstract

Background: This pilot trial was designed to determine if an optimal dose of Technosphere® insulin (TI) inhalation powder (MannKind Corp., Valencia, CA) could be used regardless of variation in meal carbohydrate (CHO) content.

Subjects and Methods: In total, eight subjects (seven men, one woman) with type 2 diabetes were enrolled. Subjects underwent dose optimization meal challenge (MC) visits (100% CHO) and MCs with varied CHO meal contents (50%, 200%, and 0% calculated CHOs). Primary end point was change in postprandial glucose (PPG) excursions. Baseline demographics were 60±7 years of age, diabetes duration of 12.3±4.27 years, hemoglobin A1c (A1C) of 7.82±1.04%, and body mass index of 31.3±5.48 kg/m2.

Results: Maximum mean PPG excursions for the nominal 100% CHO meals were −13±15 mg/dL for breakfast (B) and −14±15 mg/dL for lunch (L), similar to those after 50% CHO meals (B, −17±16 mg/dL; L, +14±10 mg/dL). The largest excursions occurred during 200% CHO meals and remained below American Diabetes Association targets (B, +19±16 mg/dL; L, +32±29 mg/dL). During 15 of the MCs, subjects took their usual TI dose and then had no meal (0% CHO). For the 0% CHO MCs, the largest mean PPG excursion were −33±9 mg/dL at 60 min (B) and −31±10 mg/dL at 60 and 90 min (L). Mean A1C dropped from 7.82±1.04% at the Week 1 visit to 6.18±0.46% (P=0.00091) at the Week 19 visit.

Conclusions: Results in eight patients suggest that once an optimal dose of TI is determined, type 2 diabetes patients can ingest meals with a wide range of CHO content or even skip meals without severe hypoglycemia. During this pilot study TI therapy improved A1C by −1.63% (P=0.00091) during 19 weeks of treatment.

http://online.liebertpub.com/doi/abs/10.1089/dia.2012.0101

Share
New Message
Please login to post a reply